Mid-Day Market Update: Crude Oil Rises 1.5%; Tarsus Pharmaceuticals Shares Slide
Midway through trading Monday, the Dow traded up 1.48% to 33,782.47 while the NASDAQ rose 0.74% to 14,134.01. The S&P also rose, gaining 1.17% to 4,215.39.
31 Stocks Moving In Monday’s Mid-Day Session
Gainers
Lydall, Inc. (NYSE: LDL) shares climbed 82.3% to $60.68 after the company agreed to be acquired by Unifrax for $61.10 per share.
Tarsus Pharmaceuticals’ TP-03 Hits Primary, Secondary Endpoints In Demodex Blepharitis Study
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) has reported topline data from Phase 2b/3 Saturn-1 trial evaluating TP-03 (lotilaner ophthalmic solution, 0.25%) in patients…
Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis; Co. Reports ‘Saturn-1 Phase 2b/3 trial met all primary and secondary endpoints’
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients,
Tarsus Pharmaceuticals, Inc. Initiates Phase 1 Callisto Trial of TP-05, a Novel, Oral, Non-Vaccine Therapeutic for the Prevention of Lyme Disease
More than 30 million Americans at risk for Lyme disease exposure, which can result in severe neurological and other debilitating symptoms
First participants dosed in single ascending dose and multiple ascending dose